文献速递血栓与止血

基因测序在慢性免疫性血小板减少症诊断检查中的作用

The role of genetic sequencing in the diagnostic workup for chronic immune thrombocytopenia.
PubMed 文献 · Blood Adv · 2025-01-01

本研究对80例慢性免疫性血小板减少症(ITP)患者进行全基因组测序或靶向 panel 测序,并在73例患者中验证,发现11%的患者携带已知致病或可能致病变异,32.5%携带意义未明变异,这些变异可影响临床管理如避免免疫抑制或评估移植资格。

要点

  • 慢性ITP患者中11%检出致病或可能致病变异,32.5%为意义未明变异。
  • 检出变异可指导避免免疫抑制(ANKRD26、GP1BB、ETV6、TUBB1、ITGB3)及评估移植资格(UNC13D)。
  • 验证队列中R15(PIDG)和R90(BPDG) panel 分别检出8%和9%的致病变异。

核心结论

  • 基因组测序可在慢性ITP患者中识别具有诊断相关性的变异,这些变异可指导治疗决策并改善患者结局。

研究设计与样本

  • 对80例慢性ITP患者的外周血样本进行全基因组测序或靶向 panel 测序,使用ThromboGenomics panel(n=72)和Genomics of Rare Immune Disorders panel(n=50),分别包含已知导致出血和血小板疾病(BPDG)或原发性免疫缺陷(PIDG)的基因。
  • 验证队列73例患者接受国民健康服务体系基因组 panel 检测,使用R90(BPDG,n=35)或R15(PIDG,n=50)。

主要发现

  • 第一队列中9例患者(11%,95%CI 5-20)检出已知致病或可能致病、致病变异;BPDG panel 中7例(10%,95%CI 4-19),PIDG panel 中2例(4%,95%CI 1-14)。
  • 第一队列中26例患者(32.5%)携带意义未明变异。
  • 验证队列中,R15(PIDG) panel 检出致病变异8%(95%CI 2-20),R90(BPDG) panel 检出9%(95%CI 2-23)。

临床怎么用

  • 检出的变异影响临床管理,例如对携带ANKRD26、GP1BB、ETV6、TUBB1和ITGB3变异的患者避免免疫抑制,以及对携带UNC13D变异的患者评估异基因造血干细胞移植资格。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Immune thrombocytopenia (ITP) is a heterogenous autoimmune disorder diagnosed by excluding other conditions. Misdiagnosis of primary ITP occurs in patients with inherited thrombocytopenia and primary immunodeficiency syndromes. This study investigates whether genetic testing for inherited thrombocytopenia or primary immunodeficiency can enhance diagnostic accuracy in ITP, and guide treatment strategies. We performed whole genome sequencing or targeted panel sequencing on peripheral blood samples in a cohort of 80 participants with chronic ITP, utilizing the ThromboGenomics panel (n = 72) and the Genomics of Rare Immune Disorders panel (n = 50) consisting of genes known to cause bleeding and platelet disorders (BPDG) or primary immuodeficiency genes (PIDG) respectively. A replication cohort of 73 patients underwent clinical genomics testing with either the R90 (BPDG, n = 35) or R15 (PIDG, n = 50) National Health Service Genomics panels. Known pathogenic or likely pathogenic, disease-causing, variants were identified in 9 patients in the first cohort (11%, 95% confidence interval [CI]: 5-20); 7 patients (10%, 95% CI: 4-19) in BPDG and 2 patients (4% CI,1-14) in PIDG. In addition, 26 patients (32.5%) carried variants of uncertain significance. In the replication cohort, 8% (95% CI, 2-20) and 9% (95% CI, 2-23) of patients had a pathogenic variant identified on the R15 (PIDG) or R90 panel (BPDG), respectively. The findings impacted clinical management such as avoidance of immunosuppression (ANKRD26, GP1BB, ETV6, TUBB1, and ITGB3) and eligibility for allogeneic stem cell transplantation (UNC13D). Our findings demonstrate that genomic sequencing identifies diagnostically relevant variants in patients with chronic ITP. Identification of these variants can guide treatment decisions and improve patient outcomes.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Joshi N, Lango-Allen H, Downes K, et al. The role of genetic sequencing in the diagnostic workup for chronic immune thrombocytopenia. Blood Adv. 2025. PMID: 39808791. doi:10.1182/bloodadvances.2024014639

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。